Moderna shares soar 150% after personalised cancer vaccine breakthrough
A new cancer vaccine, intismeran, created by Moderna and Merck, has shown positive results in a late-stage trial for high-risk melanoma patients. When paired with Keytruda, it significantly prolongs the time without cancer recurrence. This personalized vaccine uses mRNA technology for individualized treatment and has the potential to revolutionize cancer treatment.